Edwards Lifesciences Corporation
NYSEEW cost to borrow surges 145% in one week to 0.58%, though still at low absolute levels as shares remain abundant for shorting.
Options traders have swung sharply behind Edwards Lifesciences. The put/call ratio has dropped to 0.94 — the lowest reading in 52 weeks — sitting 2.3 standard deviations below its 20-day mean of 1.08. That's a clean…
Edwards Lifesciences enters the back half of August with a notable split in signals: short sellers are exiting at pace while the Street has spent the past month lifting targets and adding fresh buy ratings. The…
Snapshot as of 20 Sept 2026
Edwards Lifesciences heads into its July 23 Q2 print with an unusually sharp disconnect: a parade of analyst upgrades pulling targets higher while the stock drops to its lowest level in weeks. The analyst picture is…
Edwards Lifesciences enters its July 23 earnings date with the Street more constructive than it has been all year — and the stock's 10% monthly rally giving bulls something to point to. The analyst picture is unusually…
Edwards Lifesciences heads into its May 7 Q1 2026 results with analysts tilting bullish after a flurry of target increases — but the debate is sharpening around whether the company can defend its operating margins…
Edwards Lifesciences arrives at its Q1 2026 earnings release — due after the close today — with the most notable story running in the bears' retreat, not their advance. Short interest has dropped sharply over the past…
Edwards Lifesciences reports Q1 2026 results Wednesday after market close. The medical device maker posts earnings as short interest has declined 19% over the past week to 1.72% of float. Short sellers have backed away…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for EW — free to start on ORTEX.
Sign up for free →Open EW on ORTEX